Amgen’s US Amjevita Sales Slow While Other Growth Drivers Deliver

Sales of the Humira biosimilar increased double digits globally year over year, but declined 63% in the US versus Q1 due to inventory stockpiling.

slow start
Amjevita sales in the US got off to a slow start • Source: Shutterstock

The US launch of Amgen, Inc.’s Amjevita – the first biosimilar of AbbVie Inc.’s blockbuster Humira (adalimumab) – is off to a slow start. The company reported second quarter sales on 3 August, with US sales of Amjevita declining versus the first quarter, which the company attributed to inventory stocking associated with the launch in January.

Key Takeaways

  • Amgen reported solid second quarter financial results, including 6% top-line growth.

Amgen had the US biosimilar market to itself initially following the product launch on 31 January, but other biosimilar versions...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.